🧬Tidera Health
⚕️

Educational tool only. Does not confirm eligibility or provide medical advice. Always consult your physician before pursuing any trial.

RheumatologyICD-10: M35.0

Find Recruiting Clinical Trials for Sjögren's Syndrome

Search primary Sjögren's trials for dryness, fatigue, systemic features, and new biologic therapies.

🔍 Search Sjögren's Syndrome Trials →

About Sjögren's Syndrome

Sjögren's syndrome is a chronic autoimmune condition primarily targeting the exocrine glands, leading to severe dry eyes (xerophthalmia) and dry mouth (xerostomia), and potentially systemic involvement including fatigue, joint pain, peripheral neuropathy, and lymphoma risk. Primary Sjögren's (pSS) occurs independently; secondary Sjögren's accompanies other autoimmune diseases (RA, lupus). It predominantly affects women (9:1 ratio) with peak onset in the 4th–5th decade. Despite its prevalence, no disease-modifying therapy is approved, making clinical trials particularly critical for this patient population.

What Types of Sjögren's Syndrome Clinical Trials Exist?

Primary Sjögren's trials test B-cell depleting agents (rituximab, ianalumab), BAFF/APRIL inhibitors, type I interferon pathway inhibitors, TLR7/8 inhibitors, and JAK inhibitors. EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) for systemic features and ESSPRI for patient-reported symptoms are standard eligibility and endpoint measures. Anti-SSA/Ro antibody positivity is frequently required for systemic disease trials.

Find Recruiting Sjögren's Syndrome Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time — matching trials to your age, location, and treatment history. Free, no account required.

Search Sjögren's Syndrome Trials →

Data from ClinicalTrials.gov · Updated in real time · Educational use only

Frequently Asked Questions

What clinical trials are available for Sjögren's syndrome?▾
Recruiting Sjögren's trials include anti-CD20 B-cell depletion (rituximab, ianalumab), BAFF inhibitors, type I interferon pathway inhibitors (anifrolumab in Sjögren's), JAK inhibitors, local therapies for dry eye, and systemic symptom management studies. Given the absence of approved DMARDs, Sjögren's has one of the most active trial pipelines in rheumatology.
Does anti-SSA/Ro antibody status affect my eligibility?▾
Anti-SSA/Ro antibody positivity is required for most systemic disease trials in primary Sjögren's, as it identifies patients with confirmed autoimmune pathology and higher disease activity risk. Patients who are seronegative (anti-SSA/Ro negative) may still qualify for trials targeting symptom management (sicca symptoms, fatigue) rather than systemic inflammation.
What is ESSDAI and ESSPRI in Sjögren's trials?▾
ESSDAI (EULAR Sjögren's Syndrome Disease Activity Index) measures systemic disease activity across 12 organ domains scored by the physician. ESSPRI (EULAR Sjögren's Syndrome Patient Reported Index) captures patient-experienced symptoms: dryness, fatigue, and pain. Most trials require minimum thresholds on ESSDAI for systemic disease trials and ESSPRI for symptom-focused studies.

Related Conditions

Lupus (SLE)Rheumatoid ArthritisMultiple Sclerosis

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.